论文部分内容阅读
本研究应用大鼠急性阿霉素性心肌损伤模型,观察门冬氨酸钾镁口服液的保护作用。结果显示:阿霉素组丙二醛为32.79±27.04nmol/ml,门冬氨酸钾镁加阿霉素组为18.53±12.65nmol/ml,经统计学处理示有较显著意义,说明门冬氨酸钾镁口服液具有拮抗阿霉素性心肌损伤的作用。另外,阿霉素组和门冬氨酸钾镁加阿霉素组的肌酸激酶值分别为:306±96.73和274.43±83.45u/L,虽无统计学意义,但也提示了本药对阿霉素性心肌损伤具有保护作用的趋势。
In this study, rats with acute doxorubicin myocardial injury model was used to observe the protective effects of potassium-magnesium aspartate oral solution. The results showed that: the doxorubicin group 32.79 ± 27.04nmol / ml malondialdehyde, potassium and magnesium aspartate plus doxorubicin group was 18.53 ± 12.65nmol / ml, the statistical treatment showed more significant, indicating that the winter Potassium magnesium acid oral solution has the effect of antagonizing doxorubicin myocardial injury. In addition, the doxorubicin group and potassium magnesium aspartate plus doxorubicin group of creatine kinase values were: 306 ± 96.73 and 274.43 ± 83.45u / L, although not statistically significant, but also prompted the drug Adriamycin-induced myocardial injury has a protective effect.